BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

RENATA

All Eps Dividend Board Agm Q1 Q2 Q3

RENATA 19-Nov-2019

Trading of the shares of the Company will remain suspended on record date i.e., 20.11.2019 for AGM & EGM.

RENATA 17-Nov-2019

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 18.11.2019 to 19.11.2019. Trading of the shares of the Company will remain suspended on record date i.e., 20.11.2019 for AGM & EGM.

RENATA 14-Nov-2019

(Continuation news of RENATA): and iii) Approved the draft application of merger of Renata Limited with Renata Oncology Limited for submission to the High Court Division of the Supreme Court of Bangladesh for the amalgamation of these Companies under section 228 read with section 229 of the Companies Act, 1994. (end)

RENATA 14-Nov-2019

(Continuation news of RENATA): subject to approval from the creditors, shareholders and sanction of the High Court Division of the Supreme Court of Bangladesh and other legal/regulatory authorities; ii) Approved the draft Scheme of Amalgamation, with the exchange of 0.02 shares of Renata Limited for each share of Renata Oncology Limited based on Net Asset Value per share as on June 30, 2019, supported by audited financial statements of the two companies; (cont. 2)

RENATA 14-Nov-2019

With reference to their earlier news disseminated by DSE on 30.10.2019 the Company has further informed that the Board of Directors of the Company has approved the following business i) Considered the proposal of merger of Renata Limited (Transferee Company) with its subsidiary Renata Oncology Limited (Transferor Company) based on the draft Scheme of Amalgamation placed before the Board ("Scheme") with July 1, 2019 as the appointed date, (cont. 1)

RENATA 14-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 12.78 for July-September 2019 as against Tk. 10.46 for July-September 2018; Consolidated NOCFPS was Tk. 19.16 for July-September 2019 as against Tk. 19.07 for July-September 2018. Consolidated NAV per share was Tk. 243.58 as on September 30, 2019 and Tk. 230.90 as on June 30, 2019.

RENATA 06-Nov-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.

RENATA 30-Oct-2019

There will be no price limit on the trading of the shares of the Company today (30.10.2019) following its corporate declaration.

RENATA 30-Oct-2019

(Continuation news of RENATA): iii) Bonus shares is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit the earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post-dividend retained earning become negative or a debit balance. (end)

RENATA 30-Oct-2019

(Continuation news of RENATA): The Company has also informed that i) The bonus shares has been recommended in view to utilize its retained amount as capital for manufacturing facility expansion. ii) Bonus shares is declared out of accumulated profit. (cont.4)

Previous Next page